Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Houston Methodist study reveals how strep bacterium causes infection

17

Jun 2026

Houston Methodist study reveals how strep bacterium causes infection

A fast-rising strep bacterium has become increasingly notorious for causing serious infections in humans, including complications that can lead to muscle damage and patient death. New Houston Methodist research appearing in The American Journal of Pathology, published by Elsevier, sheds light on how Streptococcus dysgalactiae subspecies equisimilis (SDSE) causes disease and may provide important insights to aid in vaccine development.

Smartphone apps and wearables help heart disease patients stay active

17

Jun 2026

Smartphone apps and wearables help heart disease patients stay active

Smartphone apps, fitness trackers and wearable devices help people with heart disease get more physical activity in their daily lives, according to an analysis of previous research published today in the Journal of the American Heart Association, an open-access, peer-reviewed journal of the American Heart Association.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.